KRAS and familial pancreatic carcinoma: We found that VVL-DD exhibited strong antitumor capacity in pancreatic cancer models with Kras or/and p53 mutation by enhancing the accumulation of macrophages and T-cells, which provides a basis for further construction of therapeutic viruses based on this backbone.